Dr. Nagourney's Blog

Email-box.png

Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Victories in Acute Leukemia - Opportunities to Expand the Horizon
By Robert A. Nagourney, MD
The March 29, 2016 Wall Street Journal  reported a 23-year-old man with acute myeloid leukemia (AML). Using genomic (DNA) profiling a FLT3 (FMS-like tyrosine kinase-3) mutation was identified and Sorafenib, a drug that targets FLT-3, provided...
The Role of Medical Oncology in Stage IV NSCLC
By Robert A. Nagourney, MD
There has been a trend in medical oncology to add therapies, layer upon layer, until every patient receives every drug every...
The Many Faces of Lung Cancer
By Robert A. Nagourney, MD
As November is lung cancer awareness month, it is opportune to examine this disease and our changing understanding of its...
Genomic Profiling for Lung Cancer: the Good, the Bad and the Ugly
By Robert A. Nagourney, MD
Genomic profiling has gained popularity in medical oncology. Using NextGen platforms, protein coding regions of human tumors...
The Changing Landscape in Non-small Cell Lung Cancer (NSCLC)
By Robert A. Nagourney, MD
In October 2012, we published a study of patients with metastatic NSCLC whose treatment was guided by ourEVA-PCD laboratory...
What is Meaningful Improvement in Lung Cancer? A Look at NSCLC Data
By Robert A. Nagourney, MD
When asked to define what constituted pornography in his 1964 Supreme Court decision (Jacobellis versus Ohio 1964) Justice...
Stage IV NSCLC Patient From the VA Outlives Hospice
By Robert A. Nagourney, MD
For those of you who have read my book Outliving Cancer you will recognize the chapter entitled “Outliving Hospice.” It is the...

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.